Abstract：
OBJECTIVE: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL.
METHODS: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.
RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
METHODS: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals.
RESULTS: A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported.
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
摘要：
目的：自1999年以来，贝沙罗汀已被批准用于治疗晚期皮肤T细胞淋巴瘤（CTCL）。然而,关于其长期安全性和有效性的数据很少.本研究的目的是通过收集迄今为止第二大病例系列关于其长期使用与CTCL的关系来确定对贝沙罗汀的耐受性和结果。
方法：这是一个多中心的回顾性研究，回顾了216例真菌病患者（174例），或Sézary综合征（42）在19家三级转诊教学医院单独使用贝沙罗汀或与其他疗法联合使用的10年疗程中。
结果：共包括133名男性（62%）和83名女性（38%），平均年龄63.5岁（27-95岁）。在整个研究期间，共有45%的人使用贝沙罗汀单药治疗，22%的人开始服用贝沙罗汀，但最终接受了额外的治疗，13％的人接受了另一种治疗，但最终接受了贝沙罗汀，而其余20％的人自开始以来接受了联合治疗。中位疗程为20.78个月（1-114）；总有效率，70.3%。26％和45％的患者达到了完全和部分缓解率，分别。治疗耐受性良好，是最常见的毒性高甘油三酯血症（79％），高胆固醇血症（71%），和甲状腺功能减退（52%）。未报告治疗相关的5级不良事件。
结论：我们的研究证实贝沙罗汀是一种长期治疗CTCL的安全有效的疗法。
方法：这是一个多中心的回顾性研究，回顾了216例真菌病患者（174例），或Sézary综合征（42）在19家三级转诊教学医院单独使用贝沙罗汀或与其他疗法联合使用的10年疗程中。
结果：共包括133名男性（62%）和83名女性（38%），平均年龄63.5岁（27-95岁）。在整个研究期间，共有45%的人使用贝沙罗汀单药治疗，22%的人开始服用贝沙罗汀，但最终接受了额外的治疗，13％的人接受了另一种治疗，但最终接受了贝沙罗汀，而其余20％的人自开始以来接受了联合治疗。中位疗程为20.78个月（1-114）；总有效率，70.3%。26％和45％的患者达到了完全和部分缓解率，分别。治疗耐受性良好，是最常见的毒性高甘油三酯血症（79％），高胆固醇血症（71%），和甲状腺功能减退（52%）。未报告治疗相关的5级不良事件。
结论：我们的研究证实贝沙罗汀是一种长期治疗CTCL的安全有效的疗法。
